Original article: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients

A. Goldhirsch, R. D. Gelber, M. Castiglione

Research output: Contribution to journalArticle

Abstract

We analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women with breast cancer randomized to International Trial V (formerly Ludwig V). For 552 patients without axillary lymph node involvement, one course of perioperative cytotoxic drugs was compared with no-adjuvant chemotherapy. For 575 patients with node-positive disease, a single course of cytotoxic chemotherapy was compared with a prolonged treatment (6 or 7 courses). Amenorrhoea was defined as having no menstrual bleeding for a 3-month interval within the first 9 months after surgery. Amenorrhoea was observed in 21% of the 199 patients with node-negative breast cancer who received no adjuvant therapy, 31% of the 353 node-negative patients who had a single course of cytotoxic therapy, 31% of the 188 patients with node-positive disease who had the same short-duration therapy, and 68% of the 387 node-positive patients who had a prolonged adjuvant therapy. Amenorrhoea was associated with an increased disease-free survival (DFS) only in the patients with prolonged cytotoxic therapy: 4-year DFS % (±s.e.) was 68% ± 3% vs. 61% ± 5% for the amenorrhoea and the no-amenorrhoea groups, respectively, (p = 0.05). In contrast, the comparison between prolonged therapy and one single course among node-positive patients showed a much larger treatment effect (4-year DFS 66% vs. 38%, p

Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalAnnals of Oncology
Volume1
Issue number3
Publication statusPublished - 1990

Fingerprint

Chemotherapy
Adjuvant Chemotherapy
Breast Cancer
Amenorrhea
Therapy
Breast Neoplasms
Vertex of a graph
Disease-Free Survival
Therapeutics
Surgery
Treatment Effects
P-groups
Breast cancer
Node
Incidence
Drugs
Lymph Nodes
Hemorrhage
Interval
Drug Therapy

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Original article : The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. / Goldhirsch, A.; Gelber, R. D.; Castiglione, M.

In: Annals of Oncology, Vol. 1, No. 3, 1990, p. 183-188.

Research output: Contribution to journalArticle

@article{daa36612c7be44169fa6331338c6e7f4,
title = "Original article: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients",
abstract = "We analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women with breast cancer randomized to International Trial V (formerly Ludwig V). For 552 patients without axillary lymph node involvement, one course of perioperative cytotoxic drugs was compared with no-adjuvant chemotherapy. For 575 patients with node-positive disease, a single course of cytotoxic chemotherapy was compared with a prolonged treatment (6 or 7 courses). Amenorrhoea was defined as having no menstrual bleeding for a 3-month interval within the first 9 months after surgery. Amenorrhoea was observed in 21{\%} of the 199 patients with node-negative breast cancer who received no adjuvant therapy, 31{\%} of the 353 node-negative patients who had a single course of cytotoxic therapy, 31{\%} of the 188 patients with node-positive disease who had the same short-duration therapy, and 68{\%} of the 387 node-positive patients who had a prolonged adjuvant therapy. Amenorrhoea was associated with an increased disease-free survival (DFS) only in the patients with prolonged cytotoxic therapy: 4-year DFS {\%} (±s.e.) was 68{\%} ± 3{\%} vs. 61{\%} ± 5{\%} for the amenorrhoea and the no-amenorrhoea groups, respectively, (p = 0.05). In contrast, the comparison between prolonged therapy and one single course among node-positive patients showed a much larger treatment effect (4-year DFS 66{\%} vs. 38{\%}, p",
author = "A. Goldhirsch and Gelber, {R. D.} and M. Castiglione",
year = "1990",
language = "English",
volume = "1",
pages = "183--188",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Original article

T2 - The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients

AU - Goldhirsch, A.

AU - Gelber, R. D.

AU - Castiglione, M.

PY - 1990

Y1 - 1990

N2 - We analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women with breast cancer randomized to International Trial V (formerly Ludwig V). For 552 patients without axillary lymph node involvement, one course of perioperative cytotoxic drugs was compared with no-adjuvant chemotherapy. For 575 patients with node-positive disease, a single course of cytotoxic chemotherapy was compared with a prolonged treatment (6 or 7 courses). Amenorrhoea was defined as having no menstrual bleeding for a 3-month interval within the first 9 months after surgery. Amenorrhoea was observed in 21% of the 199 patients with node-negative breast cancer who received no adjuvant therapy, 31% of the 353 node-negative patients who had a single course of cytotoxic therapy, 31% of the 188 patients with node-positive disease who had the same short-duration therapy, and 68% of the 387 node-positive patients who had a prolonged adjuvant therapy. Amenorrhoea was associated with an increased disease-free survival (DFS) only in the patients with prolonged cytotoxic therapy: 4-year DFS % (±s.e.) was 68% ± 3% vs. 61% ± 5% for the amenorrhoea and the no-amenorrhoea groups, respectively, (p = 0.05). In contrast, the comparison between prolonged therapy and one single course among node-positive patients showed a much larger treatment effect (4-year DFS 66% vs. 38%, p

AB - We analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women with breast cancer randomized to International Trial V (formerly Ludwig V). For 552 patients without axillary lymph node involvement, one course of perioperative cytotoxic drugs was compared with no-adjuvant chemotherapy. For 575 patients with node-positive disease, a single course of cytotoxic chemotherapy was compared with a prolonged treatment (6 or 7 courses). Amenorrhoea was defined as having no menstrual bleeding for a 3-month interval within the first 9 months after surgery. Amenorrhoea was observed in 21% of the 199 patients with node-negative breast cancer who received no adjuvant therapy, 31% of the 353 node-negative patients who had a single course of cytotoxic therapy, 31% of the 188 patients with node-positive disease who had the same short-duration therapy, and 68% of the 387 node-positive patients who had a prolonged adjuvant therapy. Amenorrhoea was associated with an increased disease-free survival (DFS) only in the patients with prolonged cytotoxic therapy: 4-year DFS % (±s.e.) was 68% ± 3% vs. 61% ± 5% for the amenorrhoea and the no-amenorrhoea groups, respectively, (p = 0.05). In contrast, the comparison between prolonged therapy and one single course among node-positive patients showed a much larger treatment effect (4-year DFS 66% vs. 38%, p

UR - http://www.scopus.com/inward/record.url?scp=0025579152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025579152&partnerID=8YFLogxK

M3 - Article

C2 - 2261364

AN - SCOPUS:0025579152

VL - 1

SP - 183

EP - 188

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -